Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 214

1.

Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib.

Palandri F, Palumbo GA, Abruzzese E, Iurlo A, Polverelli N, Elli E, Bonifacio M, Bergamaschi M, Martino B, Tiribelli M, Benevolo G, Tieghi A, Sgherza N, Isidori A, Binotto G, Crugnola M, Heidel F, Cavazzini F, Bosi C, Auteri G, Cattaneo D, Foà R, Lemoli RM, Cuneo A, Krampera M, Bartoletti D, Cavo M, Vianelli N, Breccia M, Latagliata R.

Hematol Oncol. 2019 Apr 15. doi: 10.1002/hon.2619. [Epub ahead of print]

PMID:
30985017
2.

Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study.

Palandri F, Palumbo GA, Iurlo A, Polverelli N, Benevolo G, Breccia M, Abruzzese E, Tiribelli M, Bonifacio M, Tieghi A, Isidori A, Martino B, Sgherza N, D'Adda M, Bergamaschi M, Crugnola M, Cavazzini F, Bosi C, Binotto G, Auteri G, Latagliata R, Ibatici A, Scaffidi L, Penna D, Cattaneo D, Soci F, Trawinska M, Russo D, Cuneo A, Semenzato G, Di Raimondo F, Aversa F, Lemoli RM, Heidel F, Reggiani MLB, Bartoletti D, Cavo M, Catani L, Vianelli N.

Semin Hematol. 2018 Oct;55(4):248-255. doi: 10.1053/j.seminhematol.2018.05.013. Epub 2018 Jun 5.

PMID:
30502854
3.

Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib.

Breccia M, Bartoletti D, Bonifacio M, Palumbo GA, Polverelli N, Abruzzese E, Bergamaschi M, Tieghi A, Tiribelli M, Iurlo A, Cavazzini F, Sgherza N, Binotto G, Isidori A, D'Adda M, Crugnola M, Bosi C, Heidel F, Molica M, Scaffidi L, Cattaneo D, Latagliata R, Auteri G, Lemoli RM, Fanin R, Russo D, Aversa F, Cuneo A, Semenzato G, Catani L, Cavo M, Vianelli N, Foà R, Palandri F.

Ann Hematol. 2019 Apr;98(4):889-896. doi: 10.1007/s00277-018-3569-1. Epub 2018 Dec 4.

PMID:
30515542
4.

Haploidentical Transplants with Post-Transplant Cyclophosphamide for Relapsed or Refractory Hodgkin Lymphoma: The Role of Comorbidity Index and Pretransplant Positron Emission Tomography.

Marani C, Raiola AM, Morbelli S, Dominietto A, Ferrarazzo G, Avenoso D, Giannoni L, Varaldo R, Gualandi F, Grazia D, Lamparelli T, Bregante S, Van Lint MT, Ibatici A, Bovis F, Lemoli RM, Gobbi M, Bacigalupo A, Angelucci E.

Biol Blood Marrow Transplant. 2018 Dec;24(12):2501-2508. doi: 10.1016/j.bbmt.2018.07.025. Epub 2018 Jul 21.

PMID:
30041010
5.

Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients.

Palandri F, Catani L, Bonifacio M, Benevolo G, Heidel F, Palumbo GA, Crugnola M, Abruzzese E, Bartoletti D, Polverelli N, Bergamaschi M, Tiribelli M, Iurlo A, Breccia M, Cavazzini F, Tieghi A, Binotto G, Isidori A, Martino B, D'Adda M, Bosi C, Sabattini E, Vitolo U, Aversa F, Ibatici A, Lemoli RM, Sgherza N, Cuneo A, Martinelli G, Semenzato G, Cavo M, Vianelli N, Sapienza MR, Latagliata R.

Br J Haematol. 2018 Oct;183(1):35-46. doi: 10.1111/bjh.15497. Epub 2018 Jul 16.

PMID:
30010187
6.

Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients.

Ricciardi MR, Salvestrini V, Licchetta R, Mirabilii S, Forcato M, Gugliotta G, Salati S, Castagnetti F, Rosti G, Breccia M, Alimena G, Manfredini R, Bicciato S, Lemoli RM, Tafuri A.

Oncotarget. 2018 Apr 24;9(31):21758-21769. doi: 10.18632/oncotarget.24938. eCollection 2018 Apr 24.

7.

Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients.

Polverelli N, Palumbo GA, Binotto G, Abruzzese E, Benevolo G, Bergamaschi M, Tieghi A, Bonifacio M, Breccia M, Catani L, Tiribelli M, D'Adda M, Sgherza N, Isidori A, Cavazzini F, Martino B, Latagliata R, Crugnola M, Heidel F, Bosi C, Ibatici A, Soci F, Penna D, Scaffidi L, Aversa F, Lemoli RM, Vitolo U, Cuneo A, Russo D, Cavo M, Vianelli N, Palandri F.

Hematol Oncol. 2018 Apr 6. doi: 10.1002/hon.2509. [Epub ahead of print]

PMID:
29624703
8.

Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information.

Minetto P, Guolo F, Clavio M, Kunkl A, Colombo N, Carminati E, Fugazza G, Matarese S, Guardo D, Ballerini F, Di Grazia C, Raiola AM, Cagnetta A, Cea M, Miglino M, Lemoli RM, Gobbi M.

Br J Haematol. 2019 Feb;184(3):457-460. doi: 10.1111/bjh.15106. Epub 2018 Jan 23. No abstract available.

PMID:
29359798
9.

Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis.

Palandri F, Palumbo GA, Bonifacio M, Tiribelli M, Benevolo G, Martino B, Abruzzese E, D'Adda M, Polverelli N, Bergamaschi M, Tieghi A, Cavazzini F, Ibatici A, Crugnola M, Bosi C, Latagliata R, Di Veroli A, Scaffidi L, de Marchi F, Cerqui E, Anaclerico B, De Matteis G, Spinsanti M, Sabattini E, Catani L, Aversa F, Di Raimondo F, Vitolo U, Lemoli RM, Fanin R, Merli F, Russo D, Cuneo A, Bacchi Reggiani ML, Cavo M, Vianelli N, Breccia M.

Oncotarget. 2017 Jun 27;8(45):79073-79086. doi: 10.18632/oncotarget.18674. eCollection 2017 Oct 3.

10.

A blastic plasmacytoid dendritic cell neoplasm-like phenotype identifies a subgroup of npm1-mutated acute myeloid leukemia patients with worse prognosis.

Minetto P, Guolo F, Clavio M, Kunkl A, Colombo N, Carminati E, Giannoni L, Ballerini F, Lemoli RM, Gobbi M, Miglino M.

Am J Hematol. 2018 Feb;93(2):E33-E35. doi: 10.1002/ajh.24956. Epub 2017 Nov 17. No abstract available.

11.

Prompt detection of L-asparaginase inactivation is crucial to optimize treatment efficacy also in aggressive lymphomas.

Guolo F, Ferrari M, Minetto P, Matteo C, Clavio M, Coviello E, Ballerini F, Miglino M, Gobbi M, D'Incalci M, Lemoli RM, Zucchetti M.

Hematol Oncol. 2018 Apr;36(2):498-499. doi: 10.1002/hon.2484. Epub 2017 Oct 20. No abstract available.

PMID:
29052244
12.

Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents.

Cagnetta A, Soncini D, Orecchioni S, Talarico G, Minetto P, Guolo F, Retali V, Colombo N, Carminati E, Clavio M, Miglino M, Bergamaschi M, Nahimana A, Duchosal M, Todoerti K, Neri A, Passalacqua M, Bruzzone S, Nencioni A, Bertolini F, Gobbi M, Lemoli RM, Cea M.

Haematologica. 2018 Jan;103(1):80-90. doi: 10.3324/haematol.2017.176248. Epub 2017 Oct 12.

13.

Molecular and functional characterization of CD133+ stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cells.

Catani L, Sollazzo D, Bianchi E, Ciciarello M, Antoniani C, Foscoli L, Caraceni P, Giannone FA, Baldassarre M, Giordano R, Montemurro T, Montelatici E, D'Errico A, Andreone P, Giudice V, Curti A, Manfredini R, Lemoli RM.

Cytotherapy. 2017 Dec;19(12):1447-1461. doi: 10.1016/j.jcyt.2017.08.001. Epub 2017 Sep 14.

PMID:
28917627
14.

Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.

Salati S, Salvestrini V, Carretta C, Genovese E, Rontauroli S, Zini R, Rossi C, Ruberti S, Bianchi E, Barbieri G, Curti A, Castagnetti F, Gugliotta G, Rosti G, Bergamaschi M, Tafuri A, Tagliafico E, Lemoli R, Manfredini R.

Oncotarget. 2017 Jul 25;8(30):49451-49469. doi: 10.18632/oncotarget.17706.

15.

Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia.

Guolo F, Minetto P, Clavio M, Miglino M, Galaverna F, Raiola AM, Di Grazia C, Colombo N, Pozzi S, Ibatici A, Bagnasco S, Guardo D, Kunkl A, Ballerini F, Ghiggi C, Lemoli RM, Gobbi M, Bacigalupo A.

Haematologica. 2017 Sep;102(9):e348-e351. doi: 10.3324/haematol.2017.167254. Epub 2017 May 11. No abstract available.

16.
17.

Extracellular ATP induces apoptosis through P2X7R activation in acute myeloid leukemia cells but not in normal hematopoietic stem cells.

Salvestrini V, Orecchioni S, Talarico G, Reggiani F, Mazzetti C, Bertolini F, Orioli E, Adinolfi E, Di Virgilio F, Pezzi A, Cavo M, Lemoli RM, Curti A.

Oncotarget. 2017 Jan 24;8(4):5895-5908. doi: 10.18632/oncotarget.13927.

18.

The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling.

Forte D, Salvestrini V, Corradi G, Rossi L, Catani L, Lemoli RM, Cavo M, Curti A.

Oncotarget. 2017 Jan 10;8(2):2261-2274. doi: 10.18632/oncotarget.13664.

19.

Novel strategies of adoptive immunotherapy: How natural killer cells may change the treatment of elderly patients with acute myeloblastic leukemia.

Lemoli RM, Parisi S, Curti A.

Exp Hematol. 2017 Jan;45:10-16. doi: 10.1016/j.exphem.2016.10.007. Epub 2016 Nov 5. Review.

PMID:
27826123
20.

Autologous stem cell transplantation is still a valid option in good- and intermediate-risk AML: a GITMO survey on 809 patients autografted in first complete remission.

Saraceni F, Bruno B, Lemoli RM, Meloni G, Arcese W, Falda M, Ciceri F, Alessandrino EP, Specchia G, Scimè R, Raimondi R, Bacigalupo A, Bosi A, Onida F, Rambaldi A, Bonifazi F, Olivieri A.

Bone Marrow Transplant. 2017 Jan;52(1):163-166. doi: 10.1038/bmt.2016.233. Epub 2016 Sep 26. No abstract available.

PMID:
27668760
21.

Exploiting tumor vulnerabilities: NAD(+)-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies.

Cea M, Soncini D, Gobbi M, Lemoli RM, Cagnetta A.

Expert Rev Anticancer Ther. 2016 Sep;16(9):897-8. doi: 10.1080/14737140.2016.1212664. Epub 2016 Jul 22. No abstract available.

PMID:
27433930
22.

Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.

Cea M, Cagnetta A, Acharya C, Acharya P, Tai YT, Yang C, Lovera D, Soncini D, Miglino M, Fraternali-Orcioni G, Mastracci L, Nencioni A, Montecucco F, Monacelli F, Ballestrero A, Hideshima T, Chauhan D, Gobbi M, Lemoli RM, Munshi N, Treon SP, Anderson KC.

Clin Cancer Res. 2016 Dec 15;22(24):6099-6109. Epub 2016 Jun 10.

23.

High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.

Guolo F, Minetto P, Clavio M, Miglino M, Di Grazia C, Ballerini F, Pastori G, Guardo D, Colombo N, Kunkl A, Fugazza G, Rebesco B, Sessarego M, Lemoli RM, Bacigalupo A, Gobbi M.

Am J Hematol. 2016 Aug;91(8):755-62. doi: 10.1002/ajh.24391. Epub 2016 Jun 15.

24.

Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma.

Martino M, Lemoli RM, Girmenia C, Castagna L, Bruno B, Cavallo F, Offidani M, Scortechini I, Montanari M, Milone G, Postacchini L, Olivieri A.

Bone Marrow Transplant. 2016 Aug;51(8):1032-40. doi: 10.1038/bmt.2016.79. Epub 2016 Apr 4. Review.

25.

Long-term follow-up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Czerw T, Labopin M, Gorin NC, Giebel S, Blaise D, Meloni G, Pigneux A, Bosi A, Veelken J, Ferrara F, Schaap N, Lemoli RM, Cornelissen JJ, Beohou E, Nagler A, Mohty M.

Cancer. 2016 Jun 15;122(12):1880-7. doi: 10.1002/cncr.29990. Epub 2016 Mar 28.

26.

Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients.

Curti A, Ruggeri L, Parisi S, Bontadini A, Dan E, Motta MR, Rizzi S, Trabanelli S, Ocadlikova D, Lecciso M, Giudice V, Fruet F, Urbani E, Papayannidis C, Martinelli G, Bandini G, Bonifazi F, Lewis RE, Cavo M, Velardi A, Lemoli RM.

Clin Cancer Res. 2016 Apr 15;22(8):1914-21. doi: 10.1158/1078-0432.CCR-15-1604. Epub 2016 Jan 19.

27.

Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting).

Bruno B, Auner HW, Gahrton G, Garderet L, Festuccia M, Ladetto M, Lemoli RM, Massaia M, Morris C, Palumbo A, Schönland S, Boccadoro M, Kröger N.

Leuk Lymphoma. 2016;57(6):1256-68. doi: 10.3109/10428194.2015.1131278. Epub 2016 Jan 6. Review.

28.

Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells.

Cea M, Cagnetta A, Adamia S, Acharya C, Tai YT, Fulciniti M, Ohguchi H, Munshi A, Acharya P, Bhasin MK, Zhong L, Carrasco R, Monacelli F, Ballestrero A, Richardson P, Gobbi M, Lemoli RM, Munshi N, Hideshima T, Nencioni A, Chauhan D, Anderson KC.

Blood. 2016 Mar 3;127(9):1138-50. doi: 10.1182/blood-2015-06-649970. Epub 2015 Dec 16.

29.

Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma.

Cagnetta A, Lovera D, Grasso R, Colombo N, Canepa L, Ballerini F, Calvio M, Miglino M, Gobbi M, Lemoli R, Cea M.

Biomed Res Int. 2015;2015:943096. doi: 10.1155/2015/943096. Epub 2015 Oct 22. Review.

30.

Reinfusion of highly purified CD133+ bone marrow-derived stem/progenitor cells in patients with end-stage liver disease: A phase I clinical trial.

Andreone P, Catani L, Margini C, Brodosi L, Lorenzini S, Sollazzo D, Nicolini B, Giordano R, Montemurro T, Rizzi S, Dan E, Giudice V, Viganò M, Casadei A, Foschi FG, Malvi D, Bernardi M, Conti F, Lemoli RM.

Dig Liver Dis. 2015 Dec;47(12):1059-66. doi: 10.1016/j.dld.2015.08.018. Epub 2015 Sep 10.

PMID:
26427587
31.

Human cord blood-derived platelet lysate enhances the therapeutic activity of adipose-derived mesenchymal stromal cells isolated from Crohn's disease patients in a mouse model of colitis.

Forte D, Ciciarello M, Valerii MC, De Fazio L, Cavazza E, Giordano R, Parazzi V, Lazzari L, Laureti S, Rizzello F, Cavo M, Curti A, Lemoli RM, Spisni E, Catani L.

Stem Cell Res Ther. 2015 Sep 9;6:170. doi: 10.1186/s13287-015-0166-2.

32.

The Human Mesenchymal Stromal Cell-Derived Osteocyte Capacity to Modulate Dendritic Cell Functions Is Strictly Dependent on the Culture System.

Trabanelli S, La Manna F, Romano M, Salvestrini V, Cavo M, Ciciarello M, Lemoli RM, Curti A.

J Immunol Res. 2015;2015:526195. doi: 10.1155/2015/526195. Epub 2015 Jul 12.

33.

The tissue inhibitor of metalloproteinases 1 increases the clonogenic efficiency of human hematopoietic progenitor cells through CD63/PI3K/Akt signaling.

Rossi L, Forte D, Migliardi G, Salvestrini V, Buzzi M, Ricciardi MR, Licchetta R, Tafuri A, Bicciato S, Cavo M, Catani L, Lemoli RM, Curti A.

Exp Hematol. 2015 Nov;43(11):974-985.e1. doi: 10.1016/j.exphem.2015.07.003. Epub 2015 Jul 23.

PMID:
26213230
34.

Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes.

Balleari E, Salvetti C, Del Corso L, Filiberti R, Bacigalupo A, Bellodi A, Beltrami G, Bergamaschi M, Berisso G, Calzamiglia T, Carella AM, Cavalleri M, Da Col A, Favorini S, Forni GL, Goretti R, Miglino M, Mitscheuning L, Molinari E, Racchi O, Scudeletti M, Tassara R, Gobbi M, Lemoli R, Clavio M.

Leuk Res. 2015 Aug;39(8):846-52. doi: 10.1016/j.leukres.2015.05.007. Epub 2015 Jun 22.

PMID:
26145790
35.

Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes.

Minetto P, Guolo F, Clavio M, De Astis E, Colombo N, Grasso R, Fugazza G, Sessarego M, Lemoli RM, Gobbi M, Miglino M.

Leuk Res. 2015 Aug;39(8):866-73. doi: 10.1016/j.leukres.2015.04.011. Epub 2015 Apr 27.

PMID:
26012361
36.

PGE2-induced IDO1 inhibits the capacity of fully mature DCs to elicit an in vitro antileukemic immune response.

Trabanelli S, Lecciso M, Salvestrini V, Cavo M, Očadlíková D, Lemoli RM, Curti A.

J Immunol Res. 2015;2015:253191. doi: 10.1155/2015/253191. Epub 2015 Feb 26.

37.

CD103 marks a subset of human CD34+-derived langerin+ dendritic cells that induce T-regulatory cells via indoleamine 2,3-dioxygenase-1.

Očadlíková D, Trabanelli S, Salvestrini V, Ciciarello M, Evangelisti C, Lecciso M, Sabattini E, Righi S, Piccioli M, Pileri SA, Lemoli RM, Curti A.

Exp Hematol. 2015 Apr;43(4):268-76.e5. doi: 10.1016/j.exphem.2014.12.007. Epub 2015 Jan 10.

PMID:
25584868
38.

Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.

De Astis E, Clavio M, Raiola AM, Ghiso A, Guolo F, Minetto P, Galaverna F, Miglino M, Di Grazia C, Ballerini F, Marani C, Pastori G, Mitscheunig L, Cruciani F, Lovera D, Varaldo R, Ghiggi C, Lemoli RM, Bacigalupo A, Gobbi M.

Ann Hematol. 2014 Dec;93(12):2011-8. doi: 10.1007/s00277-014-2143-8. Epub 2014 Jul 4.

PMID:
24989345
39.

Very low rate of readmission after an early discharge outpatient model for autografting in multiple myeloma patients: an Italian multicenter retrospective study.

Martino M, Montanari M, Ferrara F, Ciceri F, Scortechini I, Palmieri S, Marktel S, Cimminiello M, Messina G, Irrera G, Offidani M, Console G, Castagna L, Milone G, Bruno B, Tripepi G, Lemoli RM, Olivieri A; Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO) – Sezione Trapianto Autologo.

Biol Blood Marrow Transplant. 2014 Jul;20(7):1026-32. doi: 10.1016/j.bbmt.2014.03.027. Epub 2014 Mar 31.

40.

Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.

Mohty M, Hübel K, Kröger N, Aljurf M, Apperley J, Basak GW, Bazarbachi A, Douglas K, Gabriel I, Garderet L, Geraldes C, Jaksic O, Kattan MW, Koristek Z, Lanza F, Lemoli RM, Mendeleeva L, Mikala G, Mikhailova N, Nagler A, Schouten HC, Selleslag D, Suciu S, Sureda A, Worel N, Wuchter P, Chabannon C, Duarte RF.

Bone Marrow Transplant. 2014 Jul;49(7):865-72. doi: 10.1038/bmt.2014.39. Epub 2014 Mar 31. Review.

PMID:
24686988
41.

The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells.

Trabanelli S, Očadlíková D, Ciciarello M, Salvestrini V, Lecciso M, Jandus C, Metz R, Evangelisti C, Laury-Kleintop L, Romero P, Prendergast GC, Curti A, Lemoli RM.

J Immunol. 2014 Feb 1;192(3):1231-40. doi: 10.4049/jimmunol.1300720. Epub 2014 Jan 3.

42.

Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma.

Lanza F, Lemoli RM, Olivieri A, Laszlo D, Martino M, Specchia G, Pavone V, Imola M, Pasini A, Milone G, Scortechini I, Todisco E, Guggiari E, Cascavilla N, Martinelli G, Rambaldi A, Bosi A.

Transfusion. 2014 Feb;54(2):331-9. doi: 10.1111/trf.12265. Epub 2013 Jun 19. Erratum in: Transfusion. 2014 Jun;54(6):1688-91.

PMID:
23781769
43.

Extracellular purines promote the differentiation of human bone marrow-derived mesenchymal stem cells to the osteogenic and adipogenic lineages.

Ciciarello M, Zini R, Rossi L, Salvestrini V, Ferrari D, Manfredini R, Lemoli RM.

Stem Cells Dev. 2013 Apr 1;22(7):1097-111. doi: 10.1089/scd.2012.0432. Epub 2012 Dec 21.

44.

New strategies for stem cell mobilization.

Lemoli RM.

Mediterr J Hematol Infect Dis. 2012;4(1):e2012066. doi: 10.4084/MJHID.2012.066. Epub 2012 Oct 3.

45.

Gpr171, a putative P2Y-like receptor, negatively regulates myeloid differentiation in murine hematopoietic progenitors.

Rossi L, Lemoli RM, Goodell MA.

Exp Hematol. 2013 Jan;41(1):102-12. doi: 10.1016/j.exphem.2012.09.007. Epub 2012 Sep 25.

46.

Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia.

Catani L, Sollazzo D, Trabanelli S, Curti A, Evangelisti C, Polverelli N, Palandri F, Baccarani M, Vianelli N, Lemoli RM.

Ann Hematol. 2013 Jan;92(1):67-78. doi: 10.1007/s00277-012-1556-5. Epub 2012 Aug 31.

PMID:
22936460
47.

Human responses against HER-2-positive cancer cells in human immune system-engrafted mice.

De Giovanni C, Nicoletti G, Landuzzi L, Romani F, Croci S, Palladini A, Murgo A, Antognoli A, Ianzano ML, Stivani V, Grosso V, Iezzi M, Stramucci L, Barbieri E, Lemoli RM, Nanni P, Lollini PL.

Br J Cancer. 2012 Oct 9;107(8):1302-9. doi: 10.1038/bjc.2012.394. Epub 2012 Aug 28.

48.

The sixth sense: hematopoietic stem cells detect danger through purinergic signaling.

Rossi L, Salvestrini V, Ferrari D, Di Virgilio F, Lemoli RM.

Blood. 2012 Sep 20;120(12):2365-75. Epub 2012 Jul 11. Review.

49.

Extracellular ATP exerts opposite effects on activated and regulatory CD4+ T cells via purinergic P2 receptor activation.

Trabanelli S, Ocadlíková D, Gulinelli S, Curti A, Salvestrini V, Vieira RP, Idzko M, Di Virgilio F, Ferrari D, Lemoli RM.

J Immunol. 2012 Aug 1;189(3):1303-10. doi: 10.4049/jimmunol.1103800. Epub 2012 Jul 2.

50.

European data on stem cell mobilization with plerixafor in patients with nonhematologic diseases: an analysis of the European consortium of stem cell mobilization.

Worel N, Apperley JF, Basak GW, Douglas KW, Gabriel IH, Geraldes C, Hübel K, Jaksic O, Koristek Z, Lanza F, Lemoli R, Mikala G, Selleslag D, Duarte RF, Mohty M.

Transfusion. 2012 Nov;52(11):2395-400. doi: 10.1111/j.1537-2995.2012.03603.x. Epub 2012 Mar 13.

PMID:
22414093

Supplemental Content

Loading ...
Support Center